Abstract Body

Background

Human T-cell lymphotropic virus type 1 (HTLV-1) infects 5–10 million people worldwide, yet only 3–5% of carriers develop severe diseases such as HTLV-1-associated myelopathy (HAM), a chronic progressive neuroinflammatory disorder characterized by spinal cord demyelination and motor disability. The pathogenesis of HAM remains incompletely understood, and reliable biomarkers for disease monitoring are lacking. Given the role of lipid metabolism in myelin integrity, investigating alterations in choline and sphingolipid pathways may provide insights into mechanisms of neurodegeneration in HAM.

Methods

We analyzed plasma metabolite profiles of 92 HTLV-1–infected individuals recruited at the Instituto de Infectologia Emílio Ribas, São Paulo, Brazil, comprising 43 asymptomatic carriers and 49 patients with HAM. All participants underwent serological confirmation by ELISA, Western Blot, and PCR. Targeted metabolomics was performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy focusing on choline, phosphatidylcholine, and sphingomyelin. Statistical analyses were conducted with GraphPad Prism v8. Normal distribution was verified, and Student’s t-test was used for group comparisons (p < 0.05 considered significant).

Results

Patients with HAM exhibited significantly lower plasma levels of key metabolites compared with asymptomatic carriers: choline (p = 0.0002), phosphatidylcholine (p = 0.0002), and sphingomyelin (p = 0.0089). These reductions were consistent across both sexes, with no significant differences observed when stratified by sex or proviral load. The findings suggest a disruption in lipid homeostasis specifically involving pathways essential for myelin sheath maintenance and neural function.

Conclusions

Our study demonstrates that HAM is associated with significant reductions in plasma levels of choline, phosphatidylcholine, and sphingomyelin, which directly implicated in neuronal membrane composition and myelin stability. These alterations likely reflect increased metabolic consumption or dysfunction in the context of chronic neuroinflammation and demyelination. The identification highlights their potential as candidate biomarkers for disease progression and offers mechanistic insights into the neurodegenerative processes underlying HAM. Future longitudinal metabolomics studies are warranted to validate these findings and to further explore lipidomic biomarkers as tools for clinical monitoring in HTLV-1 infection.

Table or Figure